ArticleFrontiers in oncology2022

The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma.

Orawan Suppramote et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.